SiteOne Therapeutics develops drugs that target sodium channels, the “wiring” in the body that transmits pain signals. Because SiteOne’s targets are located in the peripheral nervous system, they should not pose the same addiction risks as opioids, which hit receptors in the central nervous system.
The FDA approved RiVive, an over-the-counter version of naloxone nasal spray from Harm Reduction Therapeutics. It’s the second such approval from the FDA this year, following an affirmative decision in March for OTC Narcan.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.
As the pandemic rages on, the other major public health crisis in recent history has not ebbed. The opioid epidemic is worsening, but providers have kept their eye on the ball and are continuing their efforts to treat opioid use disorder and curb unnecessary prescriptions. Here is a snapshot of those efforts.
Covid-19 may have hampered investigations and led authorities to shift resources to more obvious frauds, attorneys said. But the pandemic also created new targets to investigate, including telemedicine and CARES Act funding.
Practice Fusion will pay $145 million to resolve criminal and civil allegations that it received kickbacks from an unnamed pharmaceutical company in exchange for building a clinical decision support system that could influence opioid prescriptions. The system generated more than 230 million alerts between 2016 and 2019, according to court documents.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
The Israeli drugmaker, plus AmerisourceBergen, Cardinal Health and McKesson, reached the settlement with Ohio's Cuyahoga and Summit counties. Walgreens did not manage to reach an agreement.
Shares of the company fell 40 percent Thursday following a story late Wednesday afternoon by Bloomberg, which reported that a bankruptcy filing was a potential option.
In a regulatory filing, the company said that the postponement was not unique to NKTR-181, though it may result in a delay in the FDA's approval decision for the drug.
Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in about 2,000 lawsuits regarding the drug.
Break down the silos. Take control of your provider data.
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.
Briefing documents from the Psychopharmacologic Drugs Advisory Committee earlier this week had cast doubt on the chances of a positive vote.
The Psychopharmacologic Drugs Advisory Committee will meet on Thursday to vote on whether to recommend the FDA approve the drug, ALKS 5461, an opioid for major depressive disorder.
The $50,000 challenge was sponsered by the Robert Wood Johnson Foundation to help find a tech-enabled approach to addressing substance abuse of opioids.
In the past, organs exposed to hepatitis C were typically discarded or given only to patients who already had the illness. Using them in patients who don’t have the virus could shorten the transplant wait time for hundreds of patients each year.